BR112017024000A2 - suspensão aquosa contendo nano partículas de glucocorticosteroide - Google Patents
suspensão aquosa contendo nano partículas de glucocorticosteroideInfo
- Publication number
- BR112017024000A2 BR112017024000A2 BR112017024000-9A BR112017024000A BR112017024000A2 BR 112017024000 A2 BR112017024000 A2 BR 112017024000A2 BR 112017024000 A BR112017024000 A BR 112017024000A BR 112017024000 A2 BR112017024000 A2 BR 112017024000A2
- Authority
- BR
- Brazil
- Prior art keywords
- aqueous suspension
- containing nano
- corticosteroid
- glucoside
- agent containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
[problema a ser solucionado] um objetivo é proporcionar uma suspensão aquosa contendo como um componente ativo um composto de glucocorticosteroide. o objetivo especificamente é proporcionar uma composição farmacêutica praticamente utilizável contendo como o componente ativo um composto de glucocorticosteroide. [solução] a presente invenção é para proporcionar uma suspensão aquosa contendo nano partículas de um composto de glucocorticosteroide e um estabilizador de dispersão, a suspensão aquosa contendo as nano partículas tendo um diâmetro de partícula médio de 300 nm ou menos, e um diâmetro de partícula d90 de 450 nm ou menos, composição farmacêuticas para administrações parenterais, injeções, colírios ou gotas auriculares contendo a suspensão aquosa, mais especificamente um colírio para tratamento ou prevenção de doenças inflamatórias do olho, ou uma gota auricular para tratamento ou prevenção de doenças inflamatórias do ouvido. [desenho selecionado] nenhum
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015095610 | 2015-05-08 | ||
JP2015-095610 | 2015-05-08 | ||
JPJP2015-095610 | 2015-05-08 | ||
PCT/JP2016/063752 WO2016181935A1 (ja) | 2015-05-08 | 2016-05-09 | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017024000A2 true BR112017024000A2 (pt) | 2018-07-17 |
BR112017024000B1 BR112017024000B1 (pt) | 2023-07-11 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
AU2016262185B2 (en) | 2021-05-13 |
EP3295943A1 (en) | 2018-03-21 |
JPWO2016181935A1 (ja) | 2018-02-22 |
CN107613985B (zh) | 2021-05-25 |
US11376262B2 (en) | 2022-07-05 |
EP3295943A4 (en) | 2019-01-02 |
TW201701882A (zh) | 2017-01-16 |
IL255452B (en) | 2022-08-01 |
RU2017142694A3 (pt) | 2019-11-11 |
JP6856525B2 (ja) | 2021-04-07 |
KR20180004164A (ko) | 2018-01-10 |
US20200129526A1 (en) | 2020-04-30 |
EP3295943B1 (en) | 2022-11-30 |
AU2016262185A1 (en) | 2017-12-21 |
CN107613985A (zh) | 2018-01-19 |
RU2017142694A (ru) | 2019-06-10 |
RU2747803C2 (ru) | 2021-05-14 |
KR102390014B1 (ko) | 2022-04-22 |
US10588913B2 (en) | 2020-03-17 |
FI3295943T3 (fi) | 2023-03-03 |
PT3295943T (pt) | 2023-02-02 |
TWI773641B (zh) | 2022-08-11 |
PL3295943T3 (pl) | 2023-05-08 |
ES2937023T3 (es) | 2023-03-23 |
US20180117064A1 (en) | 2018-05-03 |
CA2985171A1 (en) | 2016-11-17 |
IL255452A (en) | 2018-01-31 |
WO2016181935A1 (ja) | 2016-11-17 |
KR20210076202A (ko) | 2021-06-23 |
HUE061418T2 (hu) | 2023-06-28 |
MX2017014340A (es) | 2018-09-21 |
CA2985171C (en) | 2021-11-02 |
KR102268710B1 (ko) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017014340A (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
BR112018009644A2 (pt) | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície | |
BR112017016016A2 (pt) | composição de suspensão oftálmica | |
PH12015502587B1 (en) | Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
BR112017016093A2 (pt) | composição sólida, curativo de ferida, e, método de fabricação de uma composição | |
NZ728721A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
BR112017025631A2 (pt) | composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a | |
EP3463316A4 (en) | FUNCTIONALIZED NANOPARTICLES FOR INTRACELLULAR ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
BR112016006444A2 (pt) | derivado de triazolopirazina e uso do mesmo | |
RS54005B1 (en) | SMOKING PAPER WITH PERSONS THAT REDUCE THE POSSIBILITY OF FIRE | |
MX2019010852A (es) | Nanoparticulas a base de lipidos con estabilidad mejorada. | |
EP3608415A4 (en) | POLYHYDROXY ALKANOATE PARTICLES AND AQUATIC DISPERSION OF THE SAME | |
AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
BR112019008493A2 (pt) | composições farmacêuticas e usos das mesmas | |
CA3010981A1 (en) | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
MX2016015208A (es) | Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. | |
MX2017003436A (es) | Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. | |
EP3600324A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS | |
EP3573603A4 (en) | NANOPARTICLES FOR PROLONGED OPHTHALMIC DRUG ADMINISTRATION AND METHODS OF USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2016, OBSERVADAS AS CONDICOES LEGAIS |